Kevin Ullmann

Mar 28, 2024 | nature.com | Kevin Ullmann |Felix Manstein |Lika Drakhlis |Ulrich Martin |Nils Kriedemann |Alexandra Haase

AbstractA promising cell-therapy approach for heart failure aims at differentiating human pluripotent stem cells (hPSCs) into functional cardiomyocytes (CMs) in vitro to replace the disease-induced loss of patients’ heart muscle cells in vivo. But many challenges remain for the routine clinical application of hPSC-derived CMs (hPSC-CMs), including good manufacturing practice (GMP)-compliant production strategies.

Nov 3, 2023 | cellandgene.com | Felix Manstein |Kevin Ullmann |Robert Zweigerdt

By Felix Manstein, Kevin Ullmann, and Robert Zweigerdt Human induced pluripotent stem cells (hiPSCs) are a powerful tool for innovative approaches, such as drug discovery, in vitro disease modelling, or regenerative therapies. The DASbox® Mini Bioreactors and the DASbox Mini Bioreactor System have been tested to demonstrate their ability to systematically optimize the process parameters of a hiPSC culture in a step-by-step process.

Nov 1, 2023 | bioprocessonline.com | Aditi Shivarkar |Felix Manstein |Kevin Ullmann

Wonder how to accelerate your perfusion cell line development, media screening and optimization, and early process development? With the Mobius® Breez microbioreactor, you can rapidly collect high-quality data sets by running multiple cell culture experiments simultaneously and independently on your benchtop with only 2 mL working volume. Discover how.

Oct 5, 2023 | bioprocessonline.com | Felix Manstein |Kevin Ullmann |Robert Zweigerdt

By Felix Manstein, Kevin Ullmann, and Robert Zweigerdt Human induced pluripotent stem cells (hiPSCs) are a powerful tool for innovative approaches, such as drug discovery, in vitro disease modelling, or regenerative therapies. The DASbox® Mini Bioreactors and the DASbox Mini Bioreactor System have been tested to demonstrate their ability to systematically optimize the process parameters of a hiPSC culture in a step-by-step process.